Best health care companies in Redwood City, CA

Codexis, Inc. is an industrial biotechnology company that specializes in engineers enzymes for pharmaceutical and chemical production through biocatalysis. Codexis' technologies enable scale-up and implementation of biocatalytic solutions to optimize process development, from research to manufacturing. There are currently over 50 pharmaceutical firms using Codexis' technology, products and services in their manufacturing process development. Codexis creates its products by applying its CodeEvolver directed evolution technology platform, which introduces genetic mutations into microorganisms. Codexis, Inc. began operations as an independent company in 2002, and became a publicly traded company in 2009. They are located in Redwood City, CA USA

Revolution Medicines is developing new therapies through an innovative approach that harnesses the complex chemicals of life by reconfiguring natural substances into best-in-class medicines. REVOLUTION Medicines builds upon the vision of the company's founder, Martin D. Burke, M.D., Ph.D., professor of chemistry, University of Illinois at Urbana-Champaign, and Early Career Scientist of the Howard Hughes Medical Institute, who invented a transformative method for synthesizing original compounds that are pharmaceutically optimized analogues of complex natural products. REVOLUTION Medicines has entered into an exclusive license agreement with the University of Illinois to practice and expand this technology. REVOLUTION Medicines' approach is a rapid, standardized and powerful process for assembling simple “chemical building blocks” into refined natural product-like structures. These optimized compounds have significant potential as best-in-class drug candidates.

Auris Health engages in the development of robotics technology for medical applications. The company designs a novel dual-arm micro-surgical system for ophthalmic surgery. The company focuses on transforming medical intervention by integrating robotics, micro-instrumentation, endoscope design, sensing, and data science into one platform. It was founded in 2007 and headquartered in Redwood City, California.

Allakos Inc. develops antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 immune response plays a key role in pathology, including allergic disease, inflammation, and diseases characterized by excess production of inflammatory cells. Its antibodies target cell types implicated in allergic and inflammatory responses.

Pulmonx is the global leader in interventional procedures for the treatment of COPD. It develops and markets non-surgical technologies for the assessment and treatment of patients with severe emphysema, a progressive and life-threatening form of COPD. The Pulmonx solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The technology is supported by a compelling body of clinical evidence including over 100 published scientific articles regarding the clinical benefits of Zephyr Valves. FDA granted the Zephyr Valve a ‘breakthrough device' designation, and in June 2018 Pulmonx received FDA pre-market approval to commercialize our Zephyr Valve. The Zephyr Valve is now commercially available and physicians in more than 25 countries around the world routinely use the Zephyr Valves to improve the lives of patients with severe emphysema, with over 76,000 valves used to treat more than 19,000 patients worldwide to date.

CardioDx, a pioneer in the field of cardiovascular genomic diagnostics, is committed to improving the quality of care for patients with cardiovascular disease through the research, development, and validation of clinically important genomic tests.

Avinger, Inc., a medical device company, engages in developing catheter-based technologies for treating vascular diseases. It offers Wildcat, a catheter that helps physicians in treating peripheral artery disease. The company was founded in 2007 and is based in Redwood City, California.

Facet Biotech Corporation, a biotechnology company, engages in the identification and development of oncology drugs. Facet was formed through a spin-off of the biotechnology segment of PDL BioPharma, Inc., which was completed on December 18, 2008. It was subsequently acquired by Abbott Labs . The company is headquartered in Redwood City, California. Its products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company is also developing Elotuzumab, a monoclonal antibody in Phase I/II clinical studies, which binds to a cell surface glycoprotein that is expressed on myeloma cells and normal human cells; PDL192, a monoclonal antibody in Phase I clinical study, which binds to the tumor necrosis factor-like weak inducer of apoptosis receptor; PDL241, a monoclonal antibody in the preclinical stage for immunologic diseases; and TRU-016, a small modular immunopharmaceutical protein therapeutic in Phase I clinical studies for the treatment of B-cell malignancies, such as chronic lymphocytic leukemia and non-Hodgkin's lymphoma, as well as autoimmune and inflammatory disease indications. It has collaboration agreements with Biogen Idec Inc.; Bristol-Myers Squibb Company; and Trubion Pharmaceuticals, Inc. Facet Biotech Corporation also has license agreements with Abbott Laboratories, Inc.; Actinium Pharmaceuticals, Inc.; Genentech, Inc.; Ophthotech Corporation; Progenics Pharmaceuticals, Inc.; and Seattle Genetics, Inc.

HeartFlow is a medical technology company that provides new methods of diagnosis and treatment of cardiovascular disease. It offers HeartFlow Analysis, a non-invasive solution available in the United States, Europe, and Japan that helps a physician evaluate whether a patient has significant coronary artery disease based on anatomy and physiology.

Ascend Clinical, LLC is primarily engaged in providing professional analytic or diagnostic services to the medical profession, or to the patient on prescription of a physician.

PROCEPT BioRobotics is a clinical-stage medical device company based in Silicon Valley. The Company has developed a disruptive surgical product for transurethral resection of prostate tissue - The AquaBeam - and other treatment and diagnostic applications. The AquaBeam is a personalized image-guided tissue removal system, which utilizes proprietary heat-free high-velocity waterjet technology to resect and remove a predetermined volume of tissue with precise and automated incisions conforming to the shape of the prostate.

GenapSys is actively looking to partner with local health agencies and researchers to arm researchers with access to the insight afforded by sequencing. With its sequencing technology, the company aims to help support the control and limit the spread of current and future outbreaks. The device can run off of a standard power source and is small enough to fit in the back of a truck or be deployed at hospitals, airports, and public transportation hubs for quick results on virus samples.

Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive Karius Test that helps clinicians make rapid, treatment decisions. By mapping each patient's microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health. The Karius laboratory is CLIA-certified and CAP-accredited to perform high-complexity clinical laboratory testing.

The Pill Club is the first all-in-one healthcare service delivering birth control across the US. Backed by Stanford physicians, The Pill Club is a telemed service focused on delivering birth control, emergency contraceptives, and free gifts to promote a healthy lifestyle. With the full support of incubators such as StartX and 500 Startups, The Pill Club is driven to ensure a personalized and connected healthcare experience and to empower women to take ownership of their health and bodies, while providing access and personal freedom. The Pill Club is based in San Francisco Bay Area, delivers to all 50 states and The Pill Club Medical Group, Inc. offers a prescribing service to 34 states, as well as Washington D.C.: AL, AZ, CA, CO, CT, FL, GA, HI, IA, IL, IN, KS, KY, MA, MI, MO, MT, NC, NE, NJ, NV, NY, OH, PA, SC, UT, TN, TX, VA, VT, WA, WI, WY. The Pill Club was founded in October 2014 and is based in Mountain View, California.

Foxhollow Technologies, Inc. designs, develops, manufactures, and sells medical devices primarily for the treatment of peripheral artery disease (PAD) and other cardiovascular disease. It offers the SilverHawk Plaque Excision System, a minimally-invasive catheter system that treats PAD by removing plaque to reopen narrowed or blocked arteries. The company sells its SilverHawk Plaque Excision System through direct sales force in the United States, principally to interventional cardiologists, vascular surgeons, and interventional radiologists. It also markets the Rinspirator System, which removes thrombi or blood clots from occluded arteries in patients suffering from PAD or coronary artery disease. The company has research collaboration with Merck & Co., Inc. to analyze atherosclerotic plaque removed from patient arteries for identifying new biomarkers for atherosclerotic disease progression. The company was formerly known as ArterRx, Inc. and changed its name to FoxHollow Technologies, Inc. in October, 1996. The company was founded in 1996 and is based in Redwood City, California. As of October 4, 2007 Foxhollow Technologies, Inc. operates as a subsidiary of ev3 Inc.

Atreca is a biopharmaceutical company whose Immune Repertoire Capture™ technology revolutionizes the discovery and development of a wide range of products.

NuGEN is a provider of innovative genomics sample preparation solutions enabling scientists to access true biology in all samples, independent of type, quality and amount for analysis on leading analytical platforms. Committed to advancing the life sciences, NuGEN ensures robust and reproducible results for researchers seeking to predict disease risk and drug response, potentially shortening the path to treatment.

Daytop California is primarily engaged in providing diagnostic services, treatment, and other hospital services for specialized categories of patients, except mental.

Bolt Biotherapeutics is a biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients.